Adam Feurstein Says Clinical Data Could Be Acquired (CLDA)

According to a tweet by theStreet.com's Adam Feurstein, a Bloomberg reporter said that Clinical Data CLDA will either be acquired or market vilazodone on its own. CLDA shares have pulled back sharply in the last few minutes, but are still up 2.31% on the session at $31.07.